Jessica Geiger, MD, on an Active Trial for Immunocompromised Patients With Advanced Skin Cancer

Posted: Wednesday, March 25, 2026

Jessica Geiger, MD, of the Cleveland Clinic, discusses the phase II SWOG SN2426/NRG-HN013 Joint Study, of which she is the principal investigator. The actively recruiting trial is first evaluating the safety and preliminary efficacy of amivantamab monotherapy in patients with locoregionally incurable or metastatic cutaneous squamous cell carcinoma and an active immunosuppressed condition (in the safety run-in phase); investigators will then move on to comparing progression-free survival of amivantamab monotherapy vs cetuximab monotherapy in this patient population. 

For more information, visit ClinicalTrials.gov (identifier NCT07042295).